Rivaroxaban (RXB) is an orally active direct inhibitor of the activated serine protease Factor
Xa, given as monotherapy in the treatment of venous thromboembolism (VTE). It has been …

The purpose of this study was to investigate the efficacy of hydrophilic polymers in a solid
dispersion formulation in improving the solubility and dissolution rate of rivaroxaban (RXB) …

Rivaroxaban (RXB), a novel oral anticoagulant that directly inhibits factor Xa, is a poorly
soluble drug belonging to Biopharmaceutics Classification System (BCS) class II. In this …

This study aims to improve the RXB bioavailability using hybrid nanoparticles. A modified
melt dispersion technique created different formulas with varying GMO-SAIB: RXB and GMO …

This study aimed to investigate the use of Sucrose acetate isobutyrate (SAIB) and Glyceryl
monooleate (GMO) as co-formers for creating Cubosomes and SAIB-based nanodispersions …

This study aimed to develop microspheres using water-soluble carriers and surfactants to
improve the solubility, dissolution, and oral bioavailability of rivaroxaban (RXB). RXB-loaded …

The present study evaluates the effect of molecular mobility and molecular interactions in the
physical stability of rivaroxaban (RIV)–soluplus®(SOL) amorphous solid dispersions (ASDs) …

Rivaroxaban (RVX), an oral direct factor Xa inhibitor, is being explored as an alternative to
traditional anticoagulans. However, RVX still faces pharmacokinetic limitations and adverse …

The purpose of the currents study was to enhance bioavailability of rivaroxaban (RXB) and
reduce the food effect. RXB loaded PLGA nanoparticles (RXB-PLGA-NPs) were prepared by …

Rivaroxaban (RXB), an oral direct factor Xa inhibitor, presents innovative therapeutic profile.
However, RXB has shown adverse effects, mainly due to pharmacokinetic limitations …